1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsNCI Community Oncology Research Program (NCORP) is sponsored by National Cancer Institute (NCI). This opportunity supports mission-aligned projects and measurable outcomes.
Get alerted about grants like this
Get emailed when new opportunities from “National Cancer Institute (NCI)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required) NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required) Agency: National Institutes of Health Assistance Listings: 93. 393 -- Cancer Cause and Prevention Research Last Updated: May 21, 2026 View version history on Grants.
gov This Notice of Funding Opportunity (NOFO) is one of three NOFOs for the National Cancer Institute (NCI) Community Oncology Research Program (NCORP). NCORP is designed to enhance generalizability and dissemination of clinical trial and other human subject research study results through accrual in a variety of community settings.
The purpose of NCORP is to engage cancer patient populations, those at risk of cancer, and organizations in rigorous studies focused on cancer control, prevention, treatment and care delivery. NCORP is a community-based research network that:Designs and conducts clinical trials...
and other human subject studies for adults and children in cancer control, prevention, screening, and care delivery, as well as quality-of-life studies embedded within treatment trials;Enhances patient and provider access to treatment and imaging trials conducted under the National Clinical Trials Network (NCTN);NCORP will support the following components that will be individually awarded through the respective Request for Applications (RFAs) indicated below:NCORP Research Bases (UG1 Clinical Trials Required)(covered by this NOFO);NCORP Community Sites (UG1 Clinical Trials Not Allowed); andNCORP Academic Community Sites (UG1 Clinical Trials Not Allowed).
NCORP Research Bases will serve as the program's research hubs and are expected to:Provide an established organizational structure, with scientific and statistical leadership for developing, implementing, and analyzing multi-institutional cancer control, prevention, and care delivery (CCP&CD) clinical research, as well as quality-of-life studies embedded in treatment and imaging studies.
Assume responsibility for study operations and data management, including efficient protocol development; compliance with Food and Drug Administration (FDA) and Office of Human Research Protections (OHRP) regulatory and participant protection requirements; auditing; training; quality assurance; and support to Community Sites and Academic Community Sites.
Be based at institutions with comprehensive cancer clinical research expertise (e.g., NCI-designated Cancer Center, or healthcare research organization – including NCI's National Clinical Trials Network (NCTN) Group Operations Centers, or a cancer foundation associated with a NCTN Group).
For-profit organizations other than small businesses Special district governments Public and Indian housing authorities Federally recognized Native American tribal governments City or township governments Independent school districts Public and state institutions of higher education Private institutions of higher education Nonprofits non-higher education without 501(c)(3) Nonprofits non-higher education with 501(c)(3) Other Native American tribal organizations Refer to Section III.
Eligibility Information in the NOFO for additional information on eligibility. Foreign Organizations/Foreign Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed. Grantor contact information File name Description Last updated RFA-CA-27-006-Full-Announcement. html RFA-CA-27-006-Full-Announcement.
html May 21, 2026 02:31 PM UTC Link to additional information Closing: September 18, 2026 Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
According to the current listing, eligibility includes: Organizations that are part of the existing Florida Pediatric NCORP consortium, or other eligible institutions that can participate in NCI's broader NCORP initiatives. Confirm the full requirements in the official notice before applying.
The published deadline was July 31, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
NCI Community Oncology Research Program (NCORP) is funded by National Cancer Institute (NCI). Verify program details on the funder's official page before applying.
This opportunity targets applicants in Florida. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
The NCI Community Oncology Research Program: The New Mexico NCORP is sponsored by National Cancer Institute (NCI). This program aims to improve the quality of cancer care throughout New Mexico and eliminate the burden of differential cancer health outcomes in diverse populations, including American Indian, Hispanic, Caucasian, and rural populations. It achieves this by building innovative statewide outreach programs and fostering collaborations between community health systems and academic affiliates to increase awareness, access, and participation in NCI-sponsored cancer screening, control, prevention, therapeutic, and care delivery clinical trials.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward advances in AI and data science for biomedical and public health research. Projects must cross disciplinary boundaries.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.